Validation and comparison of simple noninvasive models for the prediction of liver fibrosis in chronic hepatitis C

Annals of Hepatology

Volumn 11, Issue 6, 2012, Pages 855-861

  Amorim, Thabata Glenda Fenili ^a   Staub, Guilherme Jönck ^a   Lazzarotto, César ^a   Silva, André Pacheco ^a   Manes, Joice ^a   Ferronato, Maria da Graça ^a   Shiozawa, Maria Beatriz Cacese ^a   Narciso Schiavon, Janaína Luz ^a   Dantas Correa, Esther Buzaglo ^a   Schiavon, Leonardo de Lucca ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

Liver cirrhosis. biomarkers. diagnosis

Indexed keywords

ADULT; ARTICLE; AST TO PLATELET RATIO INDEX; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FIB 4; HEPATITIS C; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY;

EID: 84869386985     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31410-3     Document Type: Article

References (40)

1. Hatzakis A, Wait S, Bruix J, Buti M, Carballo M, Cavaleri M, Colombo M, et al. The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference. J Vi-ral Hepat 2011; 18(Suppl. 1): 1-16.
2. Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 29(Suppl. 1): 74-81.
3. Shepard CW, Finelli L, Alter MJ. Global epidemiology of he-patitis C virus infection. Lancet Infect Dis 2005; 5: 558-67.
4. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011; 17: 107-15.
5. Ministério da Saúde. Boletim Epidemiológico das Hepatites Virais 2011. Available from: http://www.aids.gov.br/pu-blicacao/2011/boletim_epidemiologico_hepatites_viraiv_2011 [Accessed August 7, 2011].
6. Massard J, Ratziu V, Thabut D, Moussalli J, Lebray P, Benhamou Y, Poynard T. Natural history and predictors of disease severity in chronic hepatitis C. J Hepatol 2006; 44: S19-S24.
7. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, Nevens F, et al. Morbidity and mortality in com-pensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463-72.
8. Alberti A, Vario A, Ferrari A, Pistis R. Review article: chronic hepatitis C-natural history and cofactors. Ali-ment Pharmacol Ther 2005; 22(Suppl. 2): 74-8.
9. Afdhal NH. The natural history of hepatitis C. Semin Liver Dis 2004; 24(Suppl. 2): 3-8.
10. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115: 209-18.
11. Al Knawy B, Shiffman M. Percutaneous liver biopsy in clini-cal practice. Liver Int 2007; 27: 1166-73.
12. Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyr-sopoulos NT, Feng ZZ, et al. Sampling error and intraobser-ver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97: 2614-18.
13. Siddique I, El-Naga HA, Madda JP, Memon A, Hasan F. Sam-pling variability on percutaneous liver biopsy in patients with chronic hepatitis C virus infection. Scand J Gas-troenterol 2003; 38: 427-32.
14. Williams AL, Hoofnagle JH. Ratio of serum aspartate to ala-nine aminotransferase in chronic hepatitis. Relationship to cirrhosis. Gastroenterology 1988; 95: 734-9.
15. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26.
16. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Mon-taner J, Sulkowski M, et al. Development of a simple nonin-vasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317-25.
17. Gayotto LC, SBP/SBH. Visão histórica e consenso nacional sobre a classificação das hepatites crônicas. Projeto do Clube de Patologia Hepática da Sociedade Brasileira de Pa-tologia aprovado pela Sociedade Brasileira de Hepatologia. GED 2000; 19: 137-40.
18. Hanley JA, McNeil BJ. A method of comparing the areas un-der receiver operating characteristic curves derived from the same cases. Radiology 1983; 148: 839-43.
19. Pinzani M, Rombouts K, Colagrande S. Fibrosis in chronic li-ver diseases: diagnosis and management. J Hepatol 2005; 42(Suppl.): S22-S36.
20. Guha IN, Rosenberg WM. Noninvasive assessment of liver fibrosis: serum markers, imaging, and other modalities. Clin Liver Dis 2008; 12: 883-900, x.
21. Schiavon LL, Schiavon JL, Filho RJ, Sampaio JP, Lanzoni VP, Silva AE, Ferraz ML. Simple blood tests as noninvasive markers of liver fibrosis in hemodialysis patients with chronic hepatitis C virus infection. Hepatology 2007; 46: 307-14.
22. Carvalho-Filho RJ, Schiavon LL, Narciso-Schiavon JL, Sampaio JP, Lanzoni VP, Ferraz ML, Silva AE. Optimi-zed cutoffs improve performance of the aspartate aminotransferase to platelet ratio index for predicting significant liver fibrosis in human immunodeficiency vi-rus/hepatitis C virus co-infection. Liver Int 2008; 28: 486-93.
23. Shin WG, Park SH, Jang MK, Hahn TH, Kim JB, Lee MS, Kim DJ, et al. Aspartate aminotransferase to platelet ratio in-dex (APRI) can predict liver fibrosis in chronic hepatitis B. Dig Liver Dis 2008; 40: 267-74.
24. Cales P, Laine F, Boursier J, Deugnier Y, Moal V, Oberti F, Hunault G, et al. Comparison of blood tests for liver fibro-sis specific or not to NAFLD. J Hepatol 2009; 50: 165-73.
25. Shaheen AA, Myers RP. Diagnostic accuracy of the aspar-tate aminotransferase-to-platelet ratio index for the pre-diction of hepatitis C-related fibrosis: a systematic review. Hepatology 2007; 46: 912-21.
26. Lin ZH, Xin YN, Dong QJ, Wang Q, Jiang XJ, Zhan SH, Sun Y, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-rela-ted fibrosis: an updated meta-analysis. Hepatology 2011; 53: 726-36.
27. Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, Fontaine H, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. compa-rison with liver biopsy and fibrotest. Hepatology 2007; 46: 32-6.
28. Zarski JP, Sturm N, Guechot J, Paris A, Zafrani ES, Asselah T, Boisson RC, et al. Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepati-tis C: The ANRS HCEP-23 study. J Hepatol 2012; 56: 55-62.
29. Adler M, Gulbis B, Moreno C, Evrard S, Verset G, Golstein P, Frotscher B, et al. The predictive value of FIB-4 versus FibroTest, APRI, FibroIndex and Forns index to noninvasi-vely estimate fibrosis in hepatitis C and nonhepatitis C li-ver diseases. Hepatology 2008; 47: 762-3.
30. Cales P, de Ledinghen V, Halfon P, Bacq Y, Leroy V, Bour-sier J, Foucher J, et al. Evaluating the accuracy and in-creasing the reliable diagnosis rate of blood tests for liver fibrosis in chronic hepatitis C. Liver Int 2008; 28: 1352-62.
31. Hsieh YY, Tung SY, Lee K, Wu CS, Wei KL, Shen CH, Chang TS, et al. Routine blood tests to predict liver fi-brosis in chronic hepatitis C. World J Gastroenterol 2012; 18: 746-53.
32. Ahmad W, Ijaz B, Javed FT, Gull S, Kausar H, Sarwar MT, Asad S, et al. A comparison of four fibrosis indexes in chronic HCV: development of new fibrosis-cirrhosis index (FCI). BMC Gastroenterol 2011; 11: 44.
33. Guzelbulut F, Cetinkaya ZA, Sezikli M, Yasar B, Ozkara S, Ovunc AO. AST-platelet ratio index, Forns index and FIB-4 in the prediction of significant fibrosis and cirrhosis in pa-tients with chronic hepatitis C. Turk J Gastroenterol 2011; 22: 279-85.
34. Martinez SM, Fernandez-Varo G, Gonzalez P, Sampson E, Bruguera M, Navasa M, Jimenez W, et al. Assessment of li-ver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C. Aliment Pharmacol Ther 2011; 33: 138-48.
35. Giannini E, Botta F, Fasoli A, Ceppa P, Risso D, Lantieri PB, Celle G, et al. Progressive liver functional impairment is associated with an increase in AST/ALT ratio. Dig Dis Sci 1999; 44: 1249-53.
36. Giannini E, Risso D, Botta F, Chiarbonello B, Fasoli A, Mal-fatti F, Romagnoli P, et al. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in pa-tients with hepatitis C virus-related chronic liver disease. Arch Intern Med 2003; 163: 218-24.
37. Sheth SG, Flamm SL, Gordon FD, Chopra S. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C vi-rus infection. Am J Gastroenterol 1998; 93: 44-8.
38. Parise ER, Oliveira AC, Figueiredo-Mendes C, Lanzoni V, Martins J, Nader H, Ferraz ML. Noninvasive serum mar-kers in the diagnosis of structural liver damage in chronic hepatitis C virus infection. Liver Int 2006; 26: 1095-99.
39. Shaikh S, Memon MS, Ghani H, Baloch GH, Jaffery M, Shaikh K. Validation of three nonivasive markers in assessing the severity of liver fibrosis in chronic hepatitis C. J Coll Phy-sicians Surg Pak 2009; 19: 478-2.
40. Lackner C, Struber G, Liegl B, Leibl S, Ofner P, Bankuti C, Bauer B, et al. Comparison and validation of simple nonin-vasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology 2005; 41: 1376-82.